New pill could ease pain after hip surgery without opioids

NCT ID NCT07543796

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new painkiller called TRD205 for people recovering from hip replacement surgery. About 200 adults will receive either TRD205, a placebo, or an active comparator (celecoxib) to see how well it controls pain and reduces the need for rescue opioids. The goal is to find a safer, effective option for postoperative pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TRD205 tablets

What this could lead to

If successful, this could provide a new, non-opioid option for managing pain after hip replacement surgery, potentially reducing reliance on opioids.

What could go wrong

This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. The drug may not prove more effective than existing painkillers or could have unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTOPERATIVE ANALGESIA AFTER UNILATERAL HIP ARTHROPLASTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Third Affiliated Hospital of Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 130021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••